| Literature DB >> 29084208 |
L Knopfová1,2,3, E Biglieri2, N Volodko4, M Masařík5, M Hermanová6, J F Glaus Garzón2, M Dúcka1,3, T Kučírková1,3, K Souček1,3,7, J Šmarda1, P Beneš1,2,3, L Borsig2.
Abstract
Metastasis accounts for most of cancer-related deaths. Paracrine signaling between tumor cells and the stroma induces changes in the tumor microenvironment required for metastasis. Transcription factor c-Myb was associated with breast cancer (BC) progression but its role in metastasis remains unclear. Here we show that increased c-Myb expression in BC cells inhibits spontaneous lung metastasis through impaired tumor cell extravasation. On contrary, BC cells with increased lung metastatic capacity exhibited low c-Myb levels. We identified a specific inflammatory signature, including Ccl2 chemokine, that was expressed in lung metastatic cells but was suppressed in tumor cells with higher c-Myb levels. Tumor cell-derived Ccl2 expression facilitated lung metastasis and rescued trans-endothelial migration of c-Myb overexpressing cells. Clinical data show that the identified inflammatory signature, together with a MYB expression, predicts lung metastasis relapse in BC patients. These results demonstrate that the c-Myb-regulated transcriptional program in BCs results in a blunted inflammatory response and consequently suppresses lung metastasis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29084208 PMCID: PMC6711763 DOI: 10.1038/onc.2017.392
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867